Restless legs syndrome future or investigational therapies

Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Future or Investigational Therapies

Controversies

Recently, several major pharmaceutical companies are reported to be marketing drugs without an explicit approval for RLS, which are “off-label” applications for drugs approved for other diseases. The Restless Leg Foundation ^[1] received 44% of its $1.4 million in funding from these pharmaceutical groups^[2]. This has called into question the neutrality of this group (significant conflict of interest issue) and the course of action which they recommend to RLS patients.

References

Template:WH Template:WS

[1] * RLS Foundation

[2] Marshall, Jessica, and Peter Aldhous. “Patient Groups Special.” New Scientist, 10/26/06

[1]

[2]

Restless legs syndrome future or investigational therapies

Future or Investigational Therapies

Controversies

References

Looking for the patient version?